Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the calciphylaxis market?
There has been a substantial increase in the size of the calciphylaxis market in the past few years. Projected to expand from $3.22 billion in 2024 to $3.55 billion in 2025, this market is set to experience a compound annual growth rate (CAGR) of 10.0%. Factors contributing to this historical growth include an increase in chronic kidney disease cases, heightened awareness of rare diseases, government support for research into rare diseases, favorable regulatory conditions, and a rise in healthcare spending.
What will be the calciphylaxis market size in the future?
The market size of calciphylaxis is projected to experience impressive growth in the upcoming years, ballooning to $5.13 billion in 2029 with a compound annual growth rate (CAGR) of 9.7%. This predicted expansion in the forecast period is due to factors such as the increasing aged population worldwide, the introduction of innovative therapies, broader access to dialysis in emerging areas, heightened investment in drugs for rare diseases, and a surge in end-stage renal disease cases. The period in question is also likely to see key trends such as improvements in dialysis and kidney care, the evolution of treatments for mineral and bone disorders, progress in personalized medicine, biotechnological breakthroughs, therapeutic advancements, as well as enhancements in healthcare policy.
Get your calciphylaxis market report here!
https://www.thebusinessresearchcompany.com/report/calciphylaxis-global-market-report
What main drivers are fueling expansion in the calciphylaxis market?
The calciphylaxis market is projected to expand owing to the escalating occurrence of chronic kidney disease (CKD). Chronic kidney disease is a progressive condition that impairs the kidneys’ capacity to remove waste and excess fluids from the bloodstream, potentially leading to kidney failure over time. The heightened prevalence of chronic kidney disease can be linked to factors such as an aging population, an increased occurrence of diabetes and hypertension, unhealthy lifestyle habits, and inadequate early detection and management of kidney-related illnesses. Calciphylaxis is a vital marker for serious vascular complications in chronic kidney disease, emphasizing the importance for early measures and better control of mineral imbalances to prevent tissue death and associated morbidity. For example, figures from the Australian Institute of Health and Welfare show that mortality rates from CKD in December 2024 saw a gradual increase from 2021 to 2022, rising by 4.2% in 2021 and 6.2% in 2022, showing a larger increment in the latter year. Thus, the growing prevalence of chronic kidney disease is a driving factor in the advancement of the calciphylaxis market. The calciphylaxis market is also anticipated to be fueled by the rising rate of obesity. Obesity, characterized by an excessive accumulation of body fat that elevates the risk of various health complications like heart disease, diabetes and hypertension, is on the rise due to factors like inactive lifestyles, high-calorie diets, genetic factors, and restricted access to healthy food choices. The risk of developing calciphylaxis increases with obesity due to metabolic disorders, persistent inflammation, and vascular calcification, which intensify calcium-phosphate imbalance and endothelial damage, particularly in individuals with chronic kidney disease. As an example, data from the US-based Centers for Disease Control and Prevention highlighted that in 2022, the number of states with an adult obesity rate of 35% or higher grew to 22, up from 19 states in 2021. Thus, the mounting rate of obesity is contributing to the growth of the calciphylaxis market.
What key areas define the segmentation of the global calciphylaxis market?
The calciphylaxis market covered in this report is segmented –
1) By Type: Non-Uremic Calciphylaxis, Ulcers And Wounds, Debridement Of Wounds
2) By Treatment: Drug Therapy, Hyperbaric Calciphylaxis Therapy
3) By Diagnosis: Deep Skin Biopsies, Blood Tests, Imaging
4) By End-Use: Hospital And Clinics, Homecare, Ambulatory Centers
Subsegments:
1) By Non-Uremic Calciphylaxis: Vascular Calcification, Soft Tissue Calcification, Cutaneous Manifestations
2) By Ulcers and Wounds: Skin Ulcers, Ischemic Wounds, Necrotic Ulcers, Pressure Ulcers
3) By Debridement Of Wounds: Surgical Debridement, Enzymatic Debridement, Autolytic Debridement, Mechanical Debridement, Biological Debridement
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21124&type=smp
Who are the dominant players expanding their reach in the calciphylaxis market?
Major companies operating in the calciphylaxis market are Baxter International Inc., Opko Health Inc., Hope Pharmaceuticals Ltd
How are evolving market trends shaping calciphylaxis Strategies?
Leading corporations in the calciphylaxis market are honing their focus on creating novel treatments such as enzyme replacement therapy in an effort to augment positive treatment outcomes and mitigate the harshness of the disease. Enzyme Replacement Therapy or ERT is a medical procedure that involves swapping a missing or lacking enzyme within the human body. It is typically invoked for rare genetic disorders, wherein the body fails to create a specific vital enzyme needed for normal cellular functionality. For instance, Inozyme Pharma Inc., a biopharmaceutical company from the US, publicized positive temporary findings from its Phase 1 SEAPORT 1 trial of INZ-701 in patients with end-stage kidney disease (ESKD) in October 2024. The trial’s short-term data underscores the promise of INZ-701 in revamping enzyme activity essential for averting abnormal mineralization, a principal element in severe rare diseases. This therapy is crafted to replace enzymes specifically targeting ENPP1 and ABCC6 deficiencies, factors which are linked with unhealthy calcium accumulation in blood vessels and body tissues.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21124
Which regions are emerging as leaders in the calciphylaxis market?
North America was the largest region in the calciphylaxis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Neutropenia Biologic Drug Treatment Global Market Report 2025
Connected Drug Delivery Devices Global Market Report 2025
Smart Insulin Pens Global Market Report 2025
https://thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
